Clinical trialEPhase 1Completed
CART Therapy in GUCY2C-positive Digestive Tract Tumors
Clinical Study on the Safety and Efficacy of CART Cells in the Treatment of Advanced GUCY2C-positive Digestive Tract Tumors
- Outcome
- Finished, no results posted
- Phase
- EPhase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 10 October 2020
- Expected end
- 9 October 2021
- Enrollment
- 1 participants
- Sites
- 1
- Primary outcomes
- Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 July 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.
Detailed description public domain (ClinicalTrials.gov)
The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints.